Condition: Critical Limb-Threatening Ischemia · Critical Limb Ischemia · Critical Lower Limb Ischemia · Sponsor: R3 Vascular Inc.
The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Up to 30 subjects will be enrolled at approximately 3 clinical sites in Australia.
This description comes directly from the study's public registry record.
Kristine Orosz · 1 (408) 420-7446 · korosz@r3vascular.com
Jane Beggs · 1 (408) 306-8431 · jbeggs@r3vascular.com
Always discuss trial participation with your own doctor first.
| Prince of Wales Hopsital | Randwick, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06075940